Literature DB >> 25230908

The prognosis of MGMT promoter methylation in glioblastoma patients of different race: a meta-analysis.

Haiyu Yang1, Danping Wei, Kunxian Yang, Wenru Tang, Ying Luo, Jihong Zhang.   

Abstract

O(6)-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair gene. Epigenetic silencing of the MGMT promoter methylation compromises DNA repair and has been associated with longer survival in patients with glioblastoma (GBM) who receive alkylating agents. But the prognostic of MGMT promoter methylation in GBM patients of different race is still ambiguous. Based on an univariate or multivariate analysis between different race (Caucasian and Asian), a meta-analysis of the effects of MGMT promoter methylation on both progression-free survival (PFS) and overall survival (OS) among GBM patients was conducted. A total of 6,309 patients from 50 studies were involved in the analysis. Random effect models were applied to estimate the pooled hazard ratio (HR) with 95 % confidence intervals (CIs) for GBM patients of different race prognosis, the Chi square-based Q test was used to test heterogeneity. Begg's (funnel plot method) and Egger's linear regression tests were adopted to check publication bias (a bias with regard to what is likely to be published, among what is available to be published). The HR value estimated for OS was 0.524 (95 % CI 0.428-0.640) by univariate analysis and 0.427 (95 % CI 0.355-0.513) by multivariate analysis in Caucasian. The HR value estimated for OS was 0.892 (95 % CI 0.469-1.698) by univariate analysis and 0.562 (95 % CI 0.394-0.804) by multivariate analysis in Asian. The HR value estimated for PFS was 0.526 (95 % CI 0.372-0.743) by univariate analysis and 0.437 (95 % CI 0.356-0.537) by multivariate analysis in Caucasian. The HR value estimated for PFS was 0.132 (95 % CI 0.006-3.027) by multivariate analysis in Asian. This data revealed that GBM patients with MGMT promoter methylation had longer OS and PFS by univariate or multivariate analysis in Caucasian regardless of therapeutic intervention. However, GBM patients with MGMT promoter methylation only had longer OS by multivariate analysis in Asian.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25230908     DOI: 10.1007/s11064-014-1435-7

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  67 in total

1.  Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas.

Authors:  Benjamin M Ellingson; Timothy F Cloughesy; Whitney B Pope; Taryar M Zaw; Heidi Phillips; Shadi Lalezari; Phioanh L Nghiemphu; Hassana Ibrahim; Kourosh M Naeini; Robert J Harris; Albert Lai
Journal:  Neuroimage       Date:  2011-10-07       Impact factor: 6.556

2.  Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.

Authors:  Marta Brell; Avelina Tortosa; Eugenia Verger; Juan Miguel Gil; Nuria Viñolas; Salvador Villá; Juan José Acebes; Lluis Caral; Teresa Pujol; Isidro Ferrer; Teresa Ribalta; Francesc Graus
Journal:  Clin Cancer Res       Date:  2005-07-15       Impact factor: 12.531

3.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

4.  MGMT promoter methylation in plasma of glioma patients receiving temozolomide.

Authors:  Valentina Fiano; Morena Trevisan; Elisa Trevisan; Rebecca Senetta; Anna Castiglione; Carlotta Sacerdote; Anna Gillio-Tos; Laura De Marco; Chiara Grasso; Michela Magistrello; Fabrizio Tondat; Roberta Rudà; Paola Cassoni; Riccardo Soffietti; Franco Merletti
Journal:  J Neurooncol       Date:  2014-02-12       Impact factor: 4.130

5.  Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.

Authors:  Olivier L Chinot; Maryline Barrié; Stephane Fuentes; Nathalie Eudes; Sophie Lancelot; Philippe Metellus; Xavier Muracciole; Diane Braguer; L'Houcine Ouafik; Pierre-Marie Martin; Henry Dufour; Dominique Figarella-Branger
Journal:  J Clin Oncol       Date:  2007-04-20       Impact factor: 44.544

6.  Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.

Authors:  Michael Weller; Jörg Felsberg; Christian Hartmann; Hilmar Berger; Joachim P Steinbach; Johannes Schramm; Manfred Westphal; Gabriele Schackert; Matthias Simon; Jörg C Tonn; Oliver Heese; Dietmar Krex; Guido Nikkhah; Torsten Pietsch; Otmar Wiestler; Guido Reifenberger; Andreas von Deimling; Markus Loeffler
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

7.  Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.

Authors:  Panagiotis J Vlachostergios; Eleana Hatzidaki; Christina D Befani; Panagiotis Liakos; Christos N Papandreou
Journal:  Invest New Drugs       Date:  2013-05-05       Impact factor: 3.850

Review 8.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.

Authors:  Monika E Hegi; Lili Liu; James G Herman; Roger Stupp; Wolfgang Wick; Michael Weller; Minesh P Mehta; Mark R Gilbert
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

9.  MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma.

Authors:  Daina Skiriute; Paulina Vaitkiene; Viktoras Saferis; Virginija Asmoniene; Kestutis Skauminas; Vytenis Pranas Deltuva; Arimantas Tamasauskas
Journal:  BMC Cancer       Date:  2012-06-06       Impact factor: 4.430

10.  DNA methylation in glioblastoma: impact on gene expression and clinical outcome.

Authors:  Amandine Etcheverry; Marc Aubry; Marie de Tayrac; Elodie Vauleon; Rachel Boniface; Frederique Guenot; Stephan Saikali; Abderrahmane Hamlat; Laurent Riffaud; Philippe Menei; Veronique Quillien; Jean Mosser
Journal:  BMC Genomics       Date:  2010-12-14       Impact factor: 3.969

View more
  11 in total

1.  Addition of chemotherapy to hypofractionated radiotherapy for glioblastoma: practice patterns, outcomes, and predictors of survival.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  J Neurooncol       Date:  2017-10-31       Impact factor: 4.130

Review 2.  The effect of race on the prognosis of the glioblastoma patient: a brief review.

Authors:  Nitesh P Patel; Kristopher A Lyon; Jason H Huang
Journal:  Neurol Res       Date:  2019-07-04       Impact factor: 2.448

3.  A Modern Radiotherapy Series of Survival in Hispanic Patients with Glioblastoma.

Authors:  Cheng-Chia Wu; Tony J C Wang; Ashish Jani; Juan P Estrada; Timothy Ung; Daniel S Chow; Jennifer E Soun; Shumaila Saad; Yasir H Qureshi; Robyn Gartrell; Heva J Saadatmand; Anurag Saraf; Matthew D Garrett; Christopher S Grubb; Steven R Isaacson; Simon K Cheng; Michael B Sisti; Jeffrey N Bruce; Sameer A Sheth; Andrew B Lassman; Guy M McKhann
Journal:  World Neurosurg       Date:  2015-12-31       Impact factor: 2.104

4.  Genomic and Molecular Characterization of Brain Tumors in Asian and Non-Asian Patients of Los Angeles: A Single Institution Analysis.

Authors:  Courtney Duong; Thien Nguyen; John P Sheppard; Vera Ong; Lawrance K Chung; Daniel T Nagasawa; Isaac Yang
Journal:  Brain Tumor Res Treat       Date:  2017-10-31

5.  Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.

Authors:  Tae Hoon Roh; Hun Ho Park; Seok-Gu Kang; Ju Hyung Moon; Eui Hyun Kim; Chang-Ki Hong; Sung Soo Ahn; Hye Jin Choi; Jaeho Cho; Se Hoon Kim; Seung Koo Lee; Dong Seok Kim; Sun Ho Kim; Chang-Ok Suh; Kyu Sung Lee; Jong Hee Chang
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

Review 6.  Is the prognostic significance of O6-methylguanine- DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis.

Authors:  Wei Meng; Yangyang Jiang; Jie Ma
Journal:  Cancer Manag Res       Date:  2017-09-20       Impact factor: 3.989

7.  Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.

Authors:  Byung Sup Kim; Ho Jun Seol; Do-Hyun Nam; Chul-Kee Park; Il Han Kim; Tae Min Kim; Jeong Hoon Kim; Young Hyun Cho; Sang Min Yoon; Jong Hee Chang; Seok-Gu Kang; Eui Hyun Kim; Chang-Ok Suh; Tae-Young Jung; Kyung-Hwa Lee; Chae-Yong Kim; In Ah Kim; Chang-Ki Hong; Heon Yoo; Jin Hee Kim; Shin-Hyuk Kang; Min Kyu Kang; Eun-Young Kim; Sun-Hwan Kim; Dong-Sup Chung; Sun-Chul Hwang; Joon-Ho Song; Sung Jin Cho; Sun-Il Lee; Youn-Soo Lee; Kook-Jin Ahn; Se Hoon Kim; Do Hun Lim; Ho-Shin Gwak; Se-Hoon Lee; Yong-Kil Hong
Journal:  Cancer Res Treat       Date:  2016-06-27       Impact factor: 4.679

8.  The Clinical Significance of O6-Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis.

Authors:  Yu-Hang Zhao; Ze-Fen Wang; Chang-Jun Cao; Hong Weng; Cheng-Shi Xu; Kai Li; Jie-Li Li; Jing Lan; Xian-Tao Zeng; Zhi-Qiang Li
Journal:  Front Neurol       Date:  2018-03-21       Impact factor: 4.003

9.  MGMT promoter methylation in Peruvian patients with glioblastoma.

Authors:  Carolina Belmar-Lopez; Carlos A Castaneda; Miluska Castillo; Pamela García-Corrochano; Enrique Orrego; Barbara Meléndez; Sandro Casavilca; Claudio Flores; Enrique Orrego
Journal:  Ecancermedicalscience       Date:  2018-02-14

10.  Combination chemoradiotherapy with temozolomide, vincristine, and interferon-β might improve outcomes regardless of O6-methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation status in newly glioblastoma.

Authors:  Kenichiro Asano; Toshio Fumoto; Masashi Matsuzaka; Seiko Hasegawa; Naoya Suzuki; Kenichi Akasaka; Kosuke Katayama; Akihisa Kamataki; Akira Kurose; Hiroki Ohkuma
Journal:  BMC Cancer       Date:  2021-07-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.